# Azitra

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/azitra

- Industry: Biotechnology
- Headquarters: Branford, US
- Website: www.azitrainc.com
- Total disclosed funding: $34M
- Latest round: Series B (Sep 10, 2020)
- Investors on record: 5

## About

Azitra Inc. is a U.S.-based biotechnology company focused on precision dermatology, developing innovative therapeutics for adverse skin conditions through engineered live biotherapeutics and therapeutic proteins.Founded in 2014 in Branford, US, Azitra Inc. specializes in developing dermatological therapeutics. The company’s latest funding round was a PIPE in June 2023, raising USD 20.00 mn from Alumni Capital Network, bringing the total amount raised to USD 20.00 mn. The CEO is Francisco Salva, and the founder is Isabelle Lecoutre.Azitra specializes in precision dermatology through the development of innovative therapeutics for treating adverse skin conditions. Its core products include engineered live biotherapeutic products and therapeutic proteins aimed at diseases like Netherton syndrome and ichthyosis vulgaris. Key candidates in their product pipeline include ATR-12, targeted at Netherton syndrome; ATR-04 for EGFR inhibitor-associated rashes; and ATR-01 for ichthyosis vulgaris, primarily aimed at dermatology clinics and healthcare providers in North America and Europe.Azitra generated revenue of USD 7,500 in 2024, with an EBITDA of USD -10,536,905. The company’s revenue model is based on B2B partnerships with healthcare providers and pharmaceutical companies, alongside potential revenue from grants for R&D initiatives, with a focus on tiered pricing strategies and licensing agreements.In June 2023, Azitra Inc. completed an IPO, raising USD 7.50 mn by selling 1.5 million shares at USD 5 per share, which will be used for clinical trials, product development, and general corporate purposes. The company plans to launch new products targeting skin conditions and expand its market presence in North America and Europe by the end of 2024.

## Funding rounds

- Series B, Sep 10, 2020, $17M — Connecticut Innovations, Bios Partners, Leaps by Bayer
- Series A, Oct 15, 2019, $14M — Connecticut Innovations, Bios Partners, KdT Ventures, Godfrey Capital
- Series A, Apr 5, 2017, $2.9M — Bios Partners

## Investors

- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series A, Series B
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A, Series B
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series A
- Godfrey Capital — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B